Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy
- Written by PR Newswire Asia - Daily Bulletin Au RSS
BAGSVÆRD, Denmark, Nov. 6, 2020 /PRNewswire/ -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3 phase 3a trial investigated the...